GLP-1/GIP/Glucagon research
A novel triple receptor agonist (GLP-1, GIP, glucagon) studied in metabolic and weight-regulation research models.
Quantity
Dose
Women's research notes
Retatrutide is being investigated in metabolic-health research that includes female cohorts, with a focus on body-composition, glycemic and appetite-signaling endpoints.
Phase 2 trials of triple incretin agonists have included female participants and reported changes in fat mass and waist circumference as research endpoints. Researchers studying perimenopausal metabolic shifts have referenced this class for mechanistic work.
Because insulin resistance is over-represented in conditions like PCOS, researchers have examined incretin pathway agonists in female metabolic models. Retatrutide is studied at the receptor-pharmacology level, not as a treatment.
Published research describes effects on central appetite regulation. Female-specific work explores interactions with cyclic hormonal variation in pre-clinical models.
